OM
ASND icon

Opaleye Management’s Ascendis Pharma A/S ASND Stock Holding History

Opaleye Management’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-95,000
Closed -$11.2M – 46
2019
Q1 		$11.2M Buy
+95,000
New +$8.32M 3.1% 7

Other funds holding ASND

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Opaleye Management's ASND Position: Q2 2019 in Review

Opaleye Management sold out of Ascendis Pharma A/S (ASND) in Q2 2019, closing a stake of 95,000 shares — an estimated $11.2M sold.

Opaleye Management first reported a position in ASND in Q1 2019 and held it in 1 quarter. The position peaked at $11.2M in Q1 2019. 132 funds tracked by Wall St. Rank hold ASND as of Q2 2019.

  • Opaleye Management reported no remaining Ascendis Pharma A/S position as of Q2 2019 after selling out during the quarter.
  • Opaleye Management sold 95,000 Ascendis Pharma A/S shares in Q2 2019, an estimated $11.2M.
  • Opaleye Management first reported a position in Ascendis Pharma A/S in Q1 2019 and held it in 1 quarter.
  • Opaleye Management's Ascendis Pharma A/S position peaked at $11.2M in Q1 2019.
  • 132 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2019.

Based on Opaleye Management's 13F filing for Q2 2019, filed 14 Aug 2019.